Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/734—Alginic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/05—Phenols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
  • A61K33/10—Carbonates; Bicarbonates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/005—Enzyme inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
  • A61K9/0058—Chewing gums
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

• the present disclosure relates generally to methods for neutralizing stomach acid in a subject using polylysine, dextrose and grapefruit seed extract as preservatives in an alginate- based nutritional supplement and digestive aid.
• Paraben-based compounds and popular synthetics are known in the art to act as effective preservatives and digestive aids.
• paraben-based compounds are known hormone disruptors and have been implicated in the development of certain cancers.
• Alginates are natural polysaccharide polymers isolated from brown seaweed which may serve to partially address this need in the art. Alginates have been used safely as food additives for over one hundred years, with health benefits largely derived from their stable dietary fibers ease of digestion in the stomach of mammals.
• the stomach may be considered an extension of the esophagus. Following an oral intake, food remains in the stomach between one and six hours. During that time, masticated food becomes more like a thin paste or gruel and is leaked in small portions to the duodenum. In order to process this food, several enzymes are produced by the epithelial cells. Furthermore, parietal cells produce hydrochloric acid, also called stomach acid, which is responsible for the low pH in the stomach. This stomach acid is a first-line immune response to foreign organisms, providing a sterilizing effect on bacteria, fungi and other microorganisms.
• stomach acid regurgitating back to the esophagus and upper airway is a problem in the modern world.
• the esophagus and throat are not equipped to handle the low pH stomach acid contents, and injury can occur. While many are genetically and physically predisposed to reflux, lifestyle factors such as stress, over-eating, eating or drinking too quickly, and gulping down carbonated drinks can further contribute to the regurgitation of stomach contents into the esophagus and upper airway.
• Indigestion can be defined broadly as dyspepsia or GERD (Gastroesophageal reflux disease).
• Dyspepsia is a general term for the pain or discomfort a person can feel in the stomach and under the ribs, usually after eating or drinking (/. ., alcoholic beverages or coffee), although similar symptoms can occur on an empty stomach.
• GERD is a digestive disorder caused by relaxation of the ring of muscle between one’s esophagus and stomach. This ring is called the lower esophageal sphincter (LES), and the relaxation of it can further contribute to heartburn or acid indigestion.
• LES lower esophageal sphincter
• Dyspepsia may be generally relieved by antacids, which work as bases or acid-buffering agents to raise the pH of the stomach contents. Antacids are normally over-the-counter products, which can be purchased at any pharmacy. Calcium carbonate is commonly used as the active ingredient in antacids. Some calcium-based antacids add other ingredients, such as magnesium or aluminum.
• Antacids Common over- the-counter antacids include Turns® sold by GlaxoSmithKline of Brentford, England, which is simply calcium carbonate; Rennie® sold by Bayer, which has magnesium added to ease the potential side effect of constipation with too much calcium; and Maalox®, sold by Novartis, which has aluminum added to calcium carbonate and comes as liquid or tablet forms. Antacids may be useful as self-medication in dyspeptic patients with mild or moderate heartburn, however, while they are fast-acting they are also short-acting, so they are less useful for frequent or severe heartburn and do not work well as a preventive measure.
• Acid blockers such as H2 blockers and proton pump inhibitors (PPIs) are generally used for severe and chronic symptoms. These drugs work by blocking how much stomach acid is being produced. These acid blockers are not as fast-acting as antacids, but last longer and can be effective for several hours at a time.
• Over-the-counter acid blockers include Axid®, Pepcid®, Tagamet®, and Zantac®. These brands are also available in prescription strength if the milder forms do not bring enough relief.
• H2 blockers and proton pump inhibitors The clinical efficacy of H2 blockers and proton pump inhibitors is well documented (Hiirlimann S, Michel K, Inauen W, Halter F : Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo- controlled, triple cross-over study in healthy volunteers. Am ./. Gastroenterol. 1996; 91: 1173- 1180; Feldman M: Pros and cons of over-the-counter availability of histamine2-receptor antagonists.
• Acid blockers such as Pepcid®, Tagamet®, and Zantac®, work by blocking a type of histamine produced by the stomach, which in turn blocks acid production. These histamine blockers are typically taken twice a day, 30 to 60 minutes before eating to be most effective. Unfortunately, some histamine blockers have been implicated in the development of certain cancers, and many other serious, life threatening and/or life altering side effects.
• PPIs proton pump inhibitors
• PPIs proton pump inhibitors
• Prilosec® is available over the counter in the US as well as numerous other countries.
• Other PPIs such as Aciphex®, Nexium®, Prevacid®, Protonix®, and other forms of Prilosec® may require a doctor's prescription depending on the regional requirements.
• Reglan® is another prescription drug that works to reduce acid reflux by speeding up how quickly the stomach empties.
• Reglan® strengthens the digestive contractions that move food through one’s esophagus, and with this faster digestion can be associated with reduced heartburn. Reglan® and other pro-kinetic drugs have potentially mortal side effects and received a “black box” warning from the Food and Drug Administration, the agency’s strongest warning.
• Alginates are all-natural derivatives of kelp (brown seaweed) that have been used safely as natural food additives for over a hundred years.
• Alginate is a common household ingredient that is used to thicken foods and make jellies. When consumed, alginates also coat the lining of the esophagus and stomach creating a protective demulcent coating and form a protective alginate raft that floats on top of stomach contents to provide relief against acid reflux when combined with bicarbonate in the stomach.
• One of the major challenges to developing natural alginate products to help provide reflux relief is that they can form a medium for bacterial and fungal growth and are very difficult to preserve. Because of this, the primary preservative used in contemporary alginate-based products is paraben. Paraben is a synthetic preservative, a known hormone disruptor that has been implicated in hair loss, allergic reactions, and in the development of numerous cancers.
• British Patent No. 2324725 discloses a pharmaceutical composition suitable for forming a mucoadhesive lining in the gastrointestinal tract. It comprises an alginic acid or alginate salt with an M/G ratio of at least unity.
• the composition may be formulated as a liquid for treatment of reflux esophagitis.
• 32g calcium carbonate or lOOg of a 10% aluminum hydroxide gel is used per lOOg sodium alginate for the formation of a reflux preventing raft that floats on top of the stomach.
• the alginate product suffers from several adverse effects, including hormone disruption and potential carcinogenic effects from the paraben preservative required to prevent the growth of bacteria and fungi.
• W02001/087282A3 and US 2007/0281015 describe an antacid pharmaceutical composition for the rapid and prolonged neutralization of gastric acidity with mucosa-protecting activity.
• the pharmaceutical is intended as a liquid preparation for oral ingestion. It includes at least 30% of sodium alginate, an antacid soluble agent, and an inhibitor of proton pump, such as omeprazole.
• the antacid soluble agent of choice is sodium bicarbonate, which neutralizes hyperacidity acting directly in the digestive tract, the alginate forms a viscous suspension or gel after it has entered the stomach environment exerting protecting activity over gastric mucosa, and the inhibitor of a proton pump acts by selectively blocking the H+/K+- ATPase enzyme of stomach parietal cells.
• a nutritional aid/supplement or “digestion aids” containing alginates that are optimized for improved solubility, safety, taste and effectiveness.
• Said digestion aids benefit from nearly instantaneous action as well as longer lasting neutralizing effects on stomach acid, in contrast to the prior art described above.
• the herein described invention satisfies a need in art for safer, palatable, non-hormone disrupting, non-carcinogenic digestive aids, and in addition is all-natural, paraben-free, and safe.
• the present invention includes polylysine, dextrose, and grapefruit seed extract as preservatives in an alginate-based nutritional supplement product (“AP” or “digestive aid”).
• AP alginate-based nutritional supplement product
• grapefruit seed extract as preservatives in an alginate-based nutritional supplement product (“AP” or “digestive aid”).
• the present disclosure provides methods for neutralizing stomach acid in a subject, including administering to a subject an effective amount of an alginate-based product (AP), wherein AP forms a reflux-preventing raft in the stomach of a subject, and wherein AP comprises alginate and polylysine.
• AP is further adapted to neutralize acid reflux, and wherein AP further comprises a stabilizer, an alkaline salt, a secondary alkaline agent, and a salt comprising calcium.
• AP is adapted to neutralize reflux esophagitis, and wherein the alginate is formulated to inhibit proteolytic enzymes.
• inhibiting proteolytic enzymes includes inhibiting the proteolytic activity of pepsin and/or gastric juices.
• AP is further adapted to neutralize dyspepsia, and wherein AP further comprises polylysine, dextrose, and grapefruit seed extract.
• AP is adapted to act both as an antacid and a reflux- preventing raft, wherein the reflux-preventing raft comprises a foam barrier adapted to neutralize stomach acid, acid reflux, reflux esophagitis, and/or dyspepsia by reacting with gastric acid and floating upon the contents of the stomach of the subject.
• the reflux-preventing raft comprises a foam barrier adapted to neutralize stomach acid, acid reflux, reflux esophagitis, and/or dyspepsia by reacting with gastric acid and floating upon the contents of the stomach of the subject.
• AP forms a foam raft formulation with a 2.0 to 12.0% weight/volume of a low viscosity grade dextrose admixed a secondary preservative sugar.
• administering the effective amount of dextrose sugars contribute to desiccation of the product which facilitates its action as a preservative.
• AP may be formulated as a powder, syrup, and/or capsule.
• methods for producing a reflux preventing raft are also provided.
• methods for neutralizing reflux in a subject including administering to a subject an effective amount of an alginate-based product (AP), wherein AP is administered in combination with at least a carrier and MTOR compound.
• AP alginate-based product
• a first objective of the present invention is to provide methods for production and use of all-natural, safe, non-hormone disruptive, non-carcinogenic digestion aids.
• a second objective of the present invention is to provide methods of use of a digestion aid or alginate product (“AP”) that is more palatable for the user, coming in a variety of unique natural flavors optimized by a world class chef.
• AP digestion aid or alginate product
• FIG. 1 shows the chemical structure for polylysine in accordance with the preferred embodiment of the present invention
• FIG. 2 shows the chemical structure for dextrose in accordance with the preferred embodiment of the present invention
• FIG. 3 shows the chemical structure for alginic acid (“alginates”) in accordance with the preferred embodiment of the present invention.
• FIG. 4 shows a diagrammatic image of an alginate raft precipitate.
• the use of polylysine 10, dextrose 20 and grapefruit seed extract as preservatives in an alginate-based product is contemplated.
• the alginate-based product (hereafter referred to as “AP” or “alginate supplement”) is a composition that includes an alginate-based product using alginate 30 as a stabilizing agent, in addition to polylysine 10, dextrose 20 and grapefruit seed extract preservatives.
• dextrose 20 (or other common sugars known in the art) and polylysine 10 are combined to form a preservative for the alginate-based product.
• dextrose 20 (or other common sugars known in the art), grapefruit seed extract, and polylysine 10 are combined to form a preservative for the alginate-based product.
• the dextrose 20 sugars, and/or other sugars contribute to desiccation of the product which facilitates its action as a preservative.
• AP forms a demulcent (protective) barrier on the mucosal lining of the throat and esophagus of a user in order to provide relief against the partially regurgitated low pH constituents of the small intestine and stomach characteristic of gastroesophageal reflux.
• AP forms a stable protective raft 40 of foam-like composition (also referred to herein as a “gel raft”, “foam”, or “foam raft”) that serves as a pH neutral mechanical barrier reducing gastric regurgitation from the stomach to the esophagus and throat.
• foam-like composition also referred to herein as a “gel raft”, “foam”, or “foam raft”
• Reduction in regurgitation reduces exposure of the throat of a user to the low pH contents of the stomach, which otherwise contributes to local inflammation, DNA damage, pain, halitosis, and poor sleep.
• AP comprises 200 mg sodium alginate, 170 mg Vitamin B5, 200 mg sodium bicarbonate, dextrose 20, polylysine 10, and grapefruit seed extract.
• the alginate gel coats the tissues of the throat and esophagus, providing relief against acid reflux and other forms of indigestion described above.
• the 200 mg Sodium Alginate is used as a food additive, forming a foam-like and/or viscous solution or gel.
• the 170 mg Vitamin B5 (calcium pantothenate) enhances the strength and cohesiveness of the foam-like raft. Calcium increases raft strength by cross-linking alginic acid polymers 30.
• Vitamin B5 provides the unexpected result of enhanced raft strength and reduced acid reflux. Further, Vitamin B5 helps the body convert masticated carbohydrates into glucose, which the body uses to produce Adenosine Triphosphate (ATP) via aerobic metabolism. These B vitamins, often referred to as B complex vitamins, also help the body metabolize fats and protein and contribute to improved nervous system function. The AP further serves to fill the stomach and can be used as a diet aid.
• Sodium Bicarbonate enhances the utility and potency of the raft formation.
• the bicarbonate forms carbon dioxide bubbles within the alginate gel matrix, in the process, buffering out acid. This feature induces foaming action in the raft and further allows the gel to float on the surface of the gastric contents.
• Carbon dioxide also contributes to the acid neutralizing effect of AP.
• dextrose 20 serves as an all-natural sweetener and essential preservative. As described above, dextrose 20 also reduces the water content of AP which is essential to the preservative function of AP.
• polylysine 10 also serves as an essential all-natural preservative.
• grapefruit seed extract (“GSE extract”) serves as an essential all-natural preservative, antifungal, and sweetener providing a unique high concentration of antioxidants.
• AP is a low sodium, iodine-free, potassium-free alternative to many anti-reflux compositions known in the art.
• Other products known in the art contain potential carcinogens such as paraben, a known hormone disruptor, as well as high salt content, high concentrations of potassium, contributing to high blood pressure and kidney injury in some patients.
• all ingredients of AP are non- synthetic, thus ameliorating digestive and organ filtering issues.
• AP serves as a dieting aid with the utility of AP largely derived from its fibrous compounds. In the stomach of a user, said compounds expand, making the user feel satiated while contributing to a well-balanced pH environment.
• Vitamin B5 acts as a substrate for the synthesis of stress-related hormones produced in the adrenal glands.
• Vitamin B5 in AP facilitates maintenance of a healthy digestive tract and helps the body use other vitamins, particularly B2 (also called riboflavin).
• B2 also called riboflavin
• the miscibility of calcium and Vitamin B5 were contemplated by the present inventors.
• the ideal composition of ingredients included a Chilean seaweed sourcing of alginate 30 (specifically, lessonia nigrescens) formulated at a ratio of 60/40 (M/G) ratio.
• AP comprises 200 mg sodium alginate, 170 mg Vitamin B5, 200 mg sodium bicarbonate, dextrose 20, polylysine 10, and grapefruit seed extract.
• AP comprises a range of 75-400 mg sodium alginate, 100-350 mg Vitamin B5, 100-300 mg sodium bicarbonate, with dextrose 20, polylysine 10, and grapefruit seed extract included at non-specific dosages.
• AP relates to the relief of reflux esophagitis using alginates 30 specifically formulated to inhibit proteolytic enzymes.
• the invention relates to inhibiting the proteolytic activity of pepsin and/or gastric juices.
• one or more dextrose molecules 20 with a preferred molecular weight of less than 500 kDa are used in combination with polylysine 10, dextrose 20 and grapefruit seed extract preservatives.
• the composition may be in the form of a dry powder, which can be admixed with water.
• the preparations may be composed in liquid form preferably containing the amount of from 0.1 to 15% w/v of dextrose 20.
• the composition further comprises a neutralizing agent for neutralizing gastric acid such as sodium hydroxide.
• the composition preferably comprises divalent or trivalent metal cations to strengthen the formation of the foamy raft.
• the cations may be calcium or aluminum ions, for example.
• the composition may contain from 10 to 80g of calcium carbonate per lOOg dextrose 20.
• AP exercises its effect by dissolving solid calcium carbonate salt in the stomach under the influence of the acid gastric fluid, in addition to polylysine 10, dextrose 20 and grapefruit seed extract. The increasing calcium concentration will stimulate the alginate gelation as calcium ions and the polysaccharides form a rigid matrix.
• AP can act as both an antacid and a foam barrier or raft where the esophagus empties into the top of the stomach.
• the antacid, polylysine 10, dextrose 20 and grapefruit seed extract neutralize stomach acid and the foaming agent creates a physical barrier that helps provide relief from acid reflux.
• the compositions may be administered orally in the form of a dry powder or aqueous suspension which may also contain a suspending agent and/or a preservative.
• the antacid/foam formulation reacts with gastric acid to form a raft on the contents of the stomach.
• AP comprises a foam formulation with a 2.0 to 12.0% weight/volume of a low viscosity grade dextrose admixed a secondary preservative sugar.
• a liquid formulation of the antacid/foam formulation comprises an aqueous medium containing 1.5 to 10.0% weight/volume of a low viscosity grade dextrose 20 admixed with other sugars known in the art.
• a suspending agent like acrylic polymer cross-linked with 1% dextrose 20 may be used.
• improved pourability is obtained in an AP formulation wherein a liquid composition comprising potassium bicarbonate instead of other bicarbonates and at least 10% w/v sodium alginate is used in combination with polylysine 10, dextrose 20 and grapefruit seed extract as preservatives.
• the composition obtains a viscosity which does not possess thickening problems even when stored at low temperatures.
• Salt of divalent metal ions, such as calcium carbonate, are generally included in the compositions described above in an amount of 5 to 40 g/100 g dextrose 20 in order to obtain an optimal foam-like raft formation.
• a method for providing relief from reflux esophagitis as well as dyspepsia using all natural polylysine 10, dextrose 20 and grapefruit seed extract as preservatives is contemplated. As described above, this method further relates to the preparation of a pourable liquid sodium alginate composition.
• the composition preferably comprises a dextrose 20 content totaling 8 to 15% w/v.
• the composition further comprises an amount of bicarbonate. Bicarbonate may be required in order to produce adequate carbon dioxide in the stomach to obtain a proper raft formation 20
• the composition of the invention may contain a minor amount of an alkaline salt comprising a cross-linking polyvalent metal ion to support the foam-like raft, if desired, when contacted with the gastric juice.
• the raft is mechanically acting, meaning its reflux -preventing actions stem from physically obscuring access to substrate.
• the cross-linking polyvalent metal ion may be ions of calcium and aluminum and the salt may as an example be selected among calcium carbonate, CaHPCri, aluminum carbonate and aluminum hydroxide.
• the salt comprising the cross-linking polyvalent metal ion is usually present in an amount of less than 12% weight, such as less than 5% by weights, such as less than 1% by weights, such as less than 0.3% by weights, preferably less than 0.1% weight, based on the weight of the alginate.
• the salt is generally solid in the composition but is suitable highly dissolvable at a pH present in the stomach.
• AP further comprises an alkaline salt, wherein the alkaline salt is a disintegrating agent selected from the group consisting of sodium bicarbonate (NaHC03), potassium bicarbonate (KHC03), and mixtures thereof.
• the alkaline salt is a disintegrating agent selected from the group consisting of sodium bicarbonate (NaHC03), potassium bicarbonate (KHC03), and mixtures thereof.
• AP further comprises at least 2%, 4%, 8%, 10% by weight or more, based on the weight of the sodium alginate, of a further alkaline agent selected among the group consisting of magnesium hydroxide (Mg(OH)2), potassium hydroxide (KOH), sodium hydroxide (NaOH), sodium acetate (C2H302Na), and mixtures thereof.
• Mg(OH)2 magnesium hydroxide
• KOH potassium hydroxide
• NaOH sodium hydroxide
• C2H302Na sodium acetate
• AP further comprises less than 10%, 8%, 6%, or 4% by weight based on the weight of the sodium alginate of a salt comprising calcium.
• the composition further comprises an alkaline agent such as magnesium hydroxide.
• the composition further comprises an amount of sodium bicarbonate totaling 10%, 12%, 15%, or 20% by weight or more, based on the weight of the sodium alginate.
• the amount of magnesium hydroxide is 1%, 2%, or 3% by weight or more, based on the weight of the sodium alginate.
• the alginate-based product is a composition that includes alginate 30 as a stabilizing agent, in addition to polylysine 10, dextrose 20, grapefruit seed extract preservatives, with an optional minor amount of salt.
• the composition of the invention (“AP”) does not contain an added salt comprising a cross-linking polyvalent metal ion, such as a calcium salt, said salt being capable of dissolving at a pH present in the stomach. Insignificant amounts of calcium salts may be present in, for example, the tap water ingested by a user of the composition.
• At least 70%, such as 80%, preferably at least 90% of the alkali metal carboxylic acid groups of the alkali metal alginate are available for reaction with the stomach acid, i.e., is not reacted with a cross-linking polyvalent metal ion.
• the agent comprising calcium is Vitamin B5 and/or another B complex vitamin known in the art. Calcium pantothenate is alternately known as pantothenic acid or vitamin B5 or panthenol, which is a composition of 8% calcium and 92% pantothenic acid.
• compositions according to the present invention may comprise one or more acceptable carriers in addition to the active constituent s) described above.
• the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
• the alginate is purified.
• the composition may be formulated as tablets, pills, syrups, capsules, gummies, powders, etc.
• the amount of the composition required for treatment or prevention will vary according to the form of administration, the disorder to be addressed, the condition, age, the history of the subject, and the formulation of the composition, etc.
• the amount of active components are preferably effective to provide relief for the individual.
• an increased dosage of AP is required to impart the palliative effects of the GSE antioxidants.
• carrier refers to a diluent, adjuvant, excipient, or vehicle with which the active components are administered.
• the carriers in the composition may comprise a binder, such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatin, starch, lactose or lactose monohydrate; a lubricant or surfactant, such as magnesium stearate, or sodium lauryl sulphate; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as dextrose 20, sucrose or saccharin; and/or a flavoring agent, such as peppermint, methyl salicylate, orange flavoring, and/or other natural flavors.
• a binder such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), gum tragacanth, gelatin, starch, lactose or lactose monohydrate
• the AP formulation further comprises one or more enzyme cofactors, and/or one or more essential nutrients.
• exemplary cofactors include vitamin C, biotin, vitamin B5, vitamin E, and vitamin K.
• Exemplary essential nutrients are amino acids, fatty acids, etc.
• AP may also comprise one or more excipients known in the art, such as dispersing agents, wetting agents, and suspending agents. Solutions, suspensions, or emulsions of AP may also contain one or more excipients known in the art, such as dispersing agents, wetting agents, and suspending agents.
• Therapeutic formulations suitable for oral administration e.g., tablets and pills, may be obtained by compression or molding, optionally with one or more accessory ingredients.
• Compressed tablets may be prepared by mixing the constituent s) and compressing this mixture in a suitable apparatus into tablets having a suitable size.
• an alkaline metal alginate may be mixed with a binder, a lubricant, an inert diluent and/or a disintegrating agent and the alkaline salt may be mixed with a diluent, a lubricant and/or a surfactant.
• free-flowing alkaline metal alginate powder may be mixed with a binder, such as microcrystalline cellulose, and a surfactant, such as sodium lauryl sulphate, until a homogeneous mixture is obtained.
• a binder such as microcrystalline cellulose
• a surfactant such as sodium lauryl sulphate
• another binder such as polyvidone
• the alkaline salt is added under constant stirring. This mixture is passed through granulating sieves and dried by desiccation before compression into tablets in a standard compressing apparatus. Alternatively, the tablets are prepared without the addition of carriers.
• the free-flowing alkaline metal alginate is mixed with an alkaline salt before the mixture is compressed into tablets.
• Conventional methods for producing a solid form of the composition may be found in the European Pharmacopoeia, which is included herein by reference.
• a tablet may be coated or uncoated. An uncoated tablet may be scored.
• a coated tablet may be coated with sugar, shellac, film or other enteric coating agents.
• grape seed compounds comprise natural seed antioxidants, fibers, and MTOR compounds (e.g., compounds shown to act on MTOR gene signaling pathways including resveratrol).
• MTOR compounds e.g., compounds shown to act on MTOR gene signaling pathways including resveratrol
• inclusion and concentration of resveratrol enhances both the potent antioxidant features of AP but may also contribute neuro-protective and life-extension benefits to user.
• resveratrol is highly concentrated in grape skins and has been shown to extend the life span of certain laboratory mice of up to 50% when administered in high concentrations. This observation is likely linked both to the potent antioxidant action of resveratrol along with a gene-signaling/gene-regulatory effects acting through the MTOR signaling pathways, for example.
• AP there are multiple flavors of AP including vanilla caramel, mint chocolate, and/or other natural flavors. These flavors derive in part from natural antioxidant components and sugars inherent to the natural ingredients.
• AP also has a basic pH and/or infuses pH buffering compounds such that acid reflux is lessened for users. In this manner, AP can be taken as both a flavorful foodstuff and a supplement for acid reflux by a user.
• One of the unique advantages of AP is the highly flavorful product (intensity of flavor), in addition to the variety of flavors (wide range of flavors).
• the reflux preventing raft (“raft”) is produced by the steps: a) providing a functionalized natural or synthetic calcium carbonate comprising mineral, wherein said functionalized natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source; b) providing at least one polylysine-containing ingredient; c) providing at least one formulating agent comprising alginate; d) mixing the compounds provided in steps a) b) and c); e) granulating the mixture obtained in step d) by way of melt, dry or wet granulation or roller compaction.
• step “c” may include the addition of dextrose, preservatives, grapefruit seed extract, and other secondary compounds.
• parts of the formulation aid of step c) is first mixed with the functionalized calcium carbonate of step a) and the at least one polylysine- containing ingredient of step b), and the remaining portion of the formulation aid is then added to the mixture, followed by the granulation step e).
• the source of natural calcium carbonate for preparing the functionalized calcium carbonate is selected from the group of marble, calcite, chalk, Vitamin B5, limestone and dolomite and/or mixtures thereof.
• the synthetic calcium carbonate for preparing the functionalized calcium carbonate is precipitated calcium carbonate comprising aragoni tic, vateritic or calcitic mineralogical crystals forms, especially prismatic, rhombohedral or scalenohedral precipitated calcium carbonate or mixtures thereof.
• the acids are selected from the group of hydrochloric acid, sulfuric acid, sulfurous acid, hydrosulfate, phosphoric acid, phosphoric acid in combination with acetic, formic or citric acid or acid salts thereof, and mixtures thereof, preferably is phosphoric acid.
• the functionalized natural or synthetic calcium carbonate has a specific surface area of from 5 m 2 /g to 200 m 2 /g, preferably 20 m 2 /g to 150 m 2 /g, more preferably 40 m 2 /g to 100 m 2 /g, measured using nitrogen and other methods known in the art.
• the functionalized natural or synthetic calcium carbonate has a weight median grain diameter of from 0.2 to 40 pm, preferably from 0.6 to 25 pm, more preferably from 0.9 to 18 pm, still more preferably from 1 to 15 pm, measured using standard means known in the art such as Malvern Mastersizer X long bed.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Inorganic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Physiology (AREA)
• Botany (AREA)
• Biochemistry (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Nutrition Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• General Preparation And Processing Of Foods (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=84785812

Family Applications (2)

Family Applications After (1)

Country Status (8)

Families Citing this family (3)

Family Cites Families (19)

• 2022
  • 2022-07-01 MX MX2024000361A patent/MX2024000361A/es unknown
  • 2022-07-01 CA CA3224252A patent/CA3224252A1/en active Pending
  • 2022-07-01 CN CN202280059601.2A patent/CN118284424A/zh active Pending
  • 2022-07-01 AU AU2022308346A patent/AU2022308346A1/en active Pending
  • 2022-07-01 JP JP2024500622A patent/JP2024525096A/ja active Pending
  • 2022-07-01 US US17/856,542 patent/US20230000900A1/en active Pending
  • 2022-07-01 WO PCT/US2022/035992 patent/WO2023283143A2/en not_active Ceased
  • 2022-07-01 AU AU2022306572A patent/AU2022306572A1/en active Pending
  • 2022-07-01 MX MX2024000360A patent/MX2024000360A/es unknown
  • 2022-07-01 US US17/856,527 patent/US20230000899A1/en active Pending
  • 2022-07-01 JP JP2024500611A patent/JP2024525095A/ja active Pending
  • 2022-07-01 EP EP22838283.4A patent/EP4366792A4/en active Pending
  • 2022-07-01 CA CA3224263A patent/CA3224263A1/en active Pending
  • 2022-07-01 WO PCT/US2022/035986 patent/WO2023283141A1/en not_active Ceased
  • 2022-07-01 EP EP22838285.9A patent/EP4366742A4/en active Pending
  • 2022-07-01 CN CN202280059536.3A patent/CN117980012A/zh active Pending

Also Published As

Similar Documents

Legal Events